J.P. Morgan Notebook, Jan. 13: Regeneron, AstraZeneca, CRISPR And Juno
This article was originally published in The Pink Sheet Daily
Daily round-up of news and notes from the 2016 J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.